These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18452206)

  • 1. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy.
    Zabana Y; Domènech E; San Román AL; Beltrán B; Cabriada JL; Saro C; Araméndiz R; Ginard D; Hinojosa J; Gisbert JP; Mañosa M; Cabré E; Gassull MA
    Inflamm Bowel Dis; 2008 Oct; 14(10):1387-91. PubMed ID: 18452206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
    Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
    Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
    Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
    J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
    Taxonera C; Ponferrada Á; Riestra S; Bermejo F; Saro C; Martín-Arranz MD; Cabriada JL; Barreiro-de Acosta M; de Castro ML; López-Serrano P; Barrio J; Suarez C; Iglesias E; Argüelles-Arias F; Ferrer I; Marín-Jiménez I; Hernández-Camba A; Bastida G; Van Domselaar M; Martínez-Montiel P; Olivares D; Rivero M; Fernandez-Salazar L; Nantes Ó; Merino O; Alba C; Gisbert JP;
    J Crohns Colitis; 2018 Nov; 12(11):1270-1279. PubMed ID: 30052856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
    Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
    Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
    J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Ye L; Chapman TP; Wen Z; Lin L; Qiu Y; Liu Z; Ran Z; Qian J; Wu K; Gao X; Hu P; Chen M; Travis SPL; Cao Q;
    Aliment Pharmacol Ther; 2021 Feb; 53(3):390-399. PubMed ID: 33314259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
    Cagatay T; Bingol Z; Kıyan E; Yegin Z; Okumus G; Arseven O; Erkan F; Gulbaran Z; Erelel M; Ece T; Cagatay P; Kılıçaslan Z
    Clin Respir J; 2018 Apr; 12(4):1668-1675. PubMed ID: 29028148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases.
    Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Novacek G; Vogelsang H; Dejaco C; Reinisch W
    Inflamm Bowel Dis; 2011 Jan; 17(1):84-90. PubMed ID: 20722065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis.
    Cagatay T; Aydin M; Sunmez S; Cagatay P; Gulbaran Z; Gul A; Artim B; Kilicaslan Z
    Rheumatol Int; 2010 Sep; 30(11):1459-63. PubMed ID: 19844718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
    Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.